Construction of an immunotoxin with the pore forming protein StI and ior C5, a monoclonal antibody against a colon cancer cell line.
Sticholysin I (StI), a potent cytolysin isolated from the sea anemone Stichodactyla helianthus, was linked to the monoclonal antibody (mAb) ior C5. StI acts by forming hydrophilic pores in the membrane of the attacked cells leading to osmotic lysis. ior C5 is a murine IgG1, which recognizes the tumor associated antigen (TAA) ior C2. The cytolysin and the mAb were coupled by using the heterobifunctional cross-linking reagent sulfosuccinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC). Two hybrid molecules composed by one ior C5 and one or two StI molecules were obtained (named conjugated I and II, respectively). The purified conjugates were evaluated by a binding affinity assay against an ior C2-positive colon cancer cell line (SW948). Both molecules were able to recognize the antigen (Ag) in the same way that unconjugated ior C5 does. The activity of both conjugates against human erythrocytes and SW948 cells was assessed. They lost most of their hemolytic activity but their residual activity was very similar. Nevertheless, when their cytotoxicity was studied on the SW948 cell line, only conjugate II killed efficiently the cells, indicating a specific mAb-Ag interaction. In this chimeric molecule the ratio between the cytotoxic and the hemolytic activity was larger than that of the free cytolysin. This fact indicates an increase of the specificity of the toxic effect toward the SW948 cell line and consequently an increase of the difference between its hemolytic and cytotoxic doses. The results herein support the feasibility of directing StI to the surface of cancer cells expressing ior C2 Ag via the mAb ior C5.
Tejuca
M
M
Centro de Estudios de Proteínas y Departamento de Bioquímica, Facultad de Biologia, Universidad de La Habana, Cuba. tejuca@fbio.uh.cu
Díaz
I
I
Figueredo
R
R
Roque
L
L
Pazos
F
F
Martínez
D
D
Iznaga-Escobar
N
N
Pérez
R
R
Alvarez
C
C
Lanio
M E
ME
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006460:Hemolysin Proteins / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology*; D007202:Indicators and Reagents; D051379:Mice; D008807:Mice, Inbred BALB C; D009930:Organic Chemicals; D018272:Porins / Q000737:chemistry* / Q000494:pharmacology*; D013154:Spleen / Q000166:cytology / Q000187:drug effects
D000911:Antibodies, Monoclonal; D006460:Hemolysin Proteins; D000922:Immunotoxins; D007202:Indicators and Reagents; D009930:Organic Chemicals; D018272:Porins; C121348:stycholysin I